BIOMARKER FOR IDENTIFYING SUBGROUP OF EARLY-STAGE LUNG ADENOCARCINOMA PATIENTS

摘要

The preset invention relates to a biomarker for identifying the subgroup of early-stage lung adenocarcinoma patients in early-stage non-small cell lung cancer (NSCLC), which is T-lymphokine-activated killer cell-originated protein kinase (TOPK), and a therapeutic target for lung cancer.